Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Daver N, Perl AE, Maly J, Levis M, et al. J Clin Oncol 2022 Jul 18:JCO2200602. doi: 10.1200/JCO.22.00602.

Read + Share

Amedeo Smart

Independent Medical Education

Daver N, Perl AE, Maly J, Levis M, et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol 2022 Jul 18:JCO2200602. doi: 10.1200/JCO.22.00602.
PMID: 35849791